Tag: Cancer: Kidney

Validated polygenic risk score generated, with area under the curve of 0.65 among European ancestry individuals

Disease-free survival benefit was consistent with that seen in previous analyses; improvement in overall survival also seen

Patients with stromal-predominant tumors had the youngest age at diagnosis compared with other histologic subtypes

Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups

Findings seen in clear cell renal cell carcinoma patients at very high disease risk after nephrectomy from EVEREST trial

Vascular endothelial growth factor inhibitors tied to hypertension among people aged 18 to 39 years being treated for renal cancer

No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib

Progression-free survival significantly longer with addition of cabozantinib in previously untreated advanced renal cell carcinoma

Model, which considers 10 genes from UroAmp uCGP test, had high sensitivity and specificity in two validation cohorts

For patients with low-grade residual disease, complete response rate was 70 percent with UGN-101